Injective CEO Predicts U.S. ETF Before 2027

Injective Protocol CEO Eric Chen believes the U.S. could see an Injective ETF launch before 2027. Two applications for such ETFs are already under review by the Securities and Exchange Commission (SEC). In September, both 21Shares and Canary Capital updated their SEC filings, signaling progress in the approval process.

The 21Shares Injective ETF, set to trade on Nasdaq under the ticker TINJ, would hold INJ tokens directly and delegate staking decisions to the issuer. Meanwhile, Canary Capital's proposal, which would trade on Cboe BZX as INJS, aims to stake at least 90% of its U.S. institutional holdings. Chen noted that the timeline for approval appears faster than initially anticipated, though he did not provide a specific launch date.

Injective is also expanding its regulatory footprint beyond the U.S. The protocol has completed and published an INJ MiCA white paper in Europe, and it is now listed in the European Securities and Markets Authority interim register. Additionally, Injective Institutional Services became an SEC-registered transfer agent in August, marking the first step in a broader U.S. licensing strategy.

The developments come as Injective strengthens its institutional tokenization infrastructure, positioning itself for potential ETF approvals and broader market adoption.